Verified news and analysis on AI pharma — clinical milestones, financing, partnerships, and regulation. Updated regularly.
Google AI has introduced TxGemma, a new machine learning model designed to accelerate the drug discovery process. This breakthrough leverages advanced AI capabilities to enhance pharmaceutical research and development efficiency.
Anthropic has established a dedicated biological laboratory in San Francisco to test its Claude AI model in life sciences applications. This internal facility aims to complement external partnerships and advance AI-driven biological research.
ByteDance's AI drug discovery spinoff has successfully secured significant venture funding, reaching a valuation of $1.5 billion. The independent biotech startup will now operate with a specialized focus on AI-driven pharmaceutical research and development.
Artificial intelligence is expanding its footprint in RNA drug discovery, bridging the gap between small molecules and oligonucleotide therapeutics. Innovations like AlphaFold 3 are accelerating the design and development of novel RNA-targeted treatments.
AstraZeneca has entered into a strategic drug discovery collaboration and licensing agreement with Insitro, a leading artificial intelligence therapeutics company. The partnership aims to leverage Insitro's AI-driven platform to accelerate the development of new treatments.
Nvidia-backed Iambic Therapeutics has raised significant funds in its initial public offering to advance its AI-designed cancer drug candidates. The company plans to use the proceeds to fund its early-stage pipeline utilizing its molecular superintelligence platform.
Absci has reported interim Phase 1 data for ABS-201, highlighting a significantly extended half-life. This marks a major milestone as AI-designed biologics transition from computational design to wet-lab validation and clinical proof.
AstraZeneca has engaged in a massive AI drug deal, highlighting the growing role of artificial intelligence in early-stage drug discovery. The agreement tests whether AI can consistently deliver successful treatments through the final stages before regulatory approval.
Insilico Medicine has nominated ISM9546, an AI-driven oral molecular glue and peripheral-restricted VAV1 degrader, as a preclinical candidate for autoimmune diseases. This innovation highlights the company's ongoing efforts to leverage artificial intelligence in discovering novel therapeutic modalities.
Nvidia-backed AI drug developer Iambic Therapeutics has priced its initial public offering, raising approximately $150 million. The clinical-stage biotech company plans to use the funds to advance its AI-driven oncology drug pipeline and will begin trading on the Nasdaq.